RARE DISEASES A–Z · LETTER H
Hemophilia A
Hemophilia A is the classic bleeding disorder: an inherited lack of clotting factor VIII, the protein that helps blood form a firm clot. It is carried on the X chromosome, so it mainly affects boys and men, and its severity depends on how much factor VIII a person makes.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
Clotting is a cascade in which each factor activates the next, ending in a stable fibrin clot. Factor VIII is a crucial amplifier, and without it clots form too slowly and too weakly. Severity follows the factor level: severe (under 1% of normal) brings spontaneous bleeds into joints and muscles; moderate (1–5%) bleeds after minor knocks; mild (5–40%) may only declare itself after surgery or dental work. Repeated joint bleeds are the condition's long-term enemy — blood damages cartilage and bone, producing a painful, stiff 'target joint'. Bleeds into muscles can compress nerves, and bleeds in the head, throat, or abdomen are emergencies. Girls and women who carry the gene usually clot normally, but some have low enough levels to bleed significantly themselves.
How it works
Diagnosis is by blood tests: the clotting screen shows a prolonged APTT with normal other measures, and a specific factor VIII assay gives the level and hence the severity. Genetic testing identifies the F8 variant — useful for carrier testing in the family and for predicting inhibitor risk. Newborns of known carriers are tested from cord blood, because severe hemophilia can otherwise first announce itself with a bleed after delivery or immunisation. Once diagnosed, a haemophilia centre maps joint health (examination and ultrasound or MRI), checks for inhibitors regularly — antibodies against factor VIII that develop in a substantial minority of severely affected children — and screens blood-borne infections in those treated in earlier eras.
Day to day
The modern standard for severe hemophilia is prevention (prophylaxis), not just treating bleeds. Traditional prophylaxis is regular intravenous factor VIII — now often an extended half-life product needing fewer infusions — self-administered at home. A newer option is a laboratory-made antibody injected under the skin that mimics factor VIII's job, reducing bleeds and working even in people with inhibitors. Gene therapy — a one-time infusion delivering a working factor VIII gene to the liver — is approved in some countries for eligible adults. Bleeds are treated with factor as early as possible ('time is joint'), and physiotherapy protects and rehabilitates joints. Painkillers that affect clotting are avoided.
When to get help
Care is lifelong and centre-based, with at least annual joint and inhibitor review. Keep your treatment card or app record current, and ensure any hospital, dentist, or surgeon contacts the centre before procedures. Intramuscular injections and medicines that impair clotting (such as aspirin and many anti-inflammatory painkillers) need centre agreement. Vaccinations are given by routes the centre advises. Seek emergency care for head injury (even without symptoms), throat or neck swelling, severe abdominal or back pain, or a joint or muscle bleed that does not settle with home treatment. Carriers should have their own factor level checked, especially before surgery or pregnancy.
Common questions
What does a joint bleed feel like?
A bleed inside a joint (haemarthrosis) causes a distinctive tingling or bubbling sensation, then pain, swelling, warmth, and loss of movement. Treating with factor as early as possible — ideally within the first couple of hours — limits joint damage, which is why home treatment and rapid action are taught from childhood.
What do severe, moderate, and mild mean?
Factor VIII levels decide severity: severe is under 1% of normal, moderate 1–5%, and mild 5–40%. Severity predicts bleeding pattern well — but treatment is individual, and some people with moderate levels bleed like severe cases and are managed accordingly.
What is an inhibitor?
An inhibitor is an antibody the immune system makes against the replacement factor, neutralising it. Inhibitors develop in a substantial minority of people with severe hemophilia A, usually early in treatment. Standard factor then becomes ineffective, so bleeds are treated with bypassing agents or the newer antibody medicine, and immune tolerance therapy may eradicate it.
Can someone with severe hemophilia live a normal life?
Yes, increasingly. Modern prophylaxis keeps factor levels (or their equivalent, with the newer antibody treatment) high enough that many people with severe hemophilia live almost bleed-free, with healthy joints — a transformation from a generation ago.
More in Letter H
Related
Sources
- Hemophilia A (MedlinePlus)
- Hemophilia A (National Organization for Rare Disorders (NORD))
- Hereditary Factor VIII Deficiency (Hemophilia A) — Genetic and Rare Diseases Information Center (NIH GARD)
- Hemophilia (CDC)
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Factor dosing, prophylaxis, and activity advice are individual; follow your haemophilia centre's plan.